SOUTH SAN FRANCISCO, Calif. / Oct 05, 2023 / Business Wire / Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that the Company will present and host one-on-one meetings at the Jefferies Biotech CNS/Neuro Summit taking place October 11 – 12, 2023 in New York City, New York.
Jefferies Inaugural Biotech CNS/Neuro Summit Details
Fireside Chat Date and Time: Thursday, October 12, 2023 at 12:00 p.m. Pacific Time
Location: Jefferies Conference Center in New York City, New York
A webcast will be accessible through the Events page in the Investors section of the Company’s website at www.Vistagen.com. Investors interested in arranging a one-on-one meeting during the conference should contact their Jefferies representative.
About Vistagen
Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently available for the treatment of anxiety, depression, and multiple CNS disorders. Vistagen's pipeline includes six clinical-stage product candidates, including fasedienol (PH94B), itruvone (PH10), PH80, PH15, and PH284, each an investigational agent belonging to a new class of drugs known as pherines, as well as AV-101, which is an oral prodrug of an antagonist of the N-methyl-D-aspartate receptor (NMDAR). Pherines are neuroactive nasal sprays designed with an innovative proposed mechanism of action that activates chemosensory neurons in the nasal cavity and can beneficially impact key neural circuits in the brain without systemic absorption or direct activity on neurons in the brain. Vistagen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety, depression, and several other CNS disorders. Connect at www.Vistagen.com.
Last Trade: | US$2.50 |
Daily Change: | 0.25 11.11 |
Daily Volume: | 1,168,730 |
Market Cap: | US$69.600M |
November 14, 2024 November 07, 2024 September 23, 2024 August 13, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB